Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders

Trends in Neurosciences

Volumn 22, Issue 2, 1999, Pages 67-74

  Sarter, Martin ^a   Bruno, John P ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY NEUROSIS; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DEMENTIA; DRUG DEPENDENCE; HUMAN; INFORMATION PROCESSING; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; PHOBIA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

EID: 0033082462     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(98)01289-2     Document Type: Review

References (95)

1. 1 Woolf N.J. Prog. Neurobiol. 37:1991;475-524.
2. 2 Lysakowski A.et al. Neuroscience. 28:1989;291-336.
3. 3 Rasmusson D.F., Szerb J.C. Brain Res. 104:1976;243-259.
4. 4 Jimenez-Capdeville M.E., Dykes R.W. Neuroscience. 71:1996;567-579.
5. 5 Himmelheber A.M., Sarter M., Bruno J.P. Neuroscience. 86:1998;949-957.
6. 6 Sarter M., Bruno J.P. Brain Res. Rev. 23:1997;28-46.
7. 7 Sillito A.M., Murphy P.C. Jones E.G., Peters A. The Cholinergic Modulation of Cortical Function. 1987;161-185 Plenum Press.
8. 8 Metherate R., Weinberger N.M. Synapse. 6:1990;133-145.
9. 9 Kilgard M.P., Merzenich M.M. Science. 279:1998;1714-1718.
10. 10 Tremblay N., Warren R.A., Dykes R.W. J. Neurophysiol. 64:1990;1199-1211.
11. 11 Everitt B.J., Robbins T.W. Annu. Rev. Psychol. 48:1997;649-684.
12. 12 Sarter M.et al. Cognit. Brain Res. 3:1996;329-343.
13. 13 Himmelheber A.M., Sarter M., Bruno J.P. Cognit. Brain Res. 6:1997;23-36.
14. 14 Gill T.M.et al. Soc. Neurosci. Abstr. 23:1997;1839.
15. 15 Imperato A.et al. Neurochem. Int. 20:1992;S265.
16. 16 Inglis F.M., Fibiger H.C. Neuroscience. 66:1995;81-86.
17. 17 Robbins T.W. Parasuraman R. The Attentive Brain. 1998;189-220 MIT Press.
18. 18 Muir J.L., Everitt B.J., Robbins T.W. J. Neurosci. 14:1994;2313-2326.
19. 19 McGaughy J., Kaiser T., Sarter M. Behav. Neurosci. 110:1996;247-256.
20. 20 Turchi J., Sarter M. Cognit. Brain Res. 6:1997;147-158.
21. 21 Geula C., Mesulam M-M. Cerebr. Cortex. 6:1996;165-177.
22. 22 Lehericy S.et al. J. Comp. Neurol. 330:1991;15-31.
23. 23 Palmer A.M. Neurodegeneration. 5:1996;381-391.
24. 24 Palmer A.M.et al. J. Neurochem. 48:1987;8-15.
25. 25 Holttum J.R., Gershon S. Dementia. 3:1992;174-185.
26. 26 Sarter M., Bruno J.P., Himmelheber A.M. Brioni J.E., Decker M.W. Pharmacological Treatment of Alzheimer's Disease: Molecular, Neurobiological Foundations. 1997;105-128 Wiley-Liss.
27. 27 Sarter M., Bruno J.P., Dudchenko P. Psychopharmacology. 101:1990;1-17.
28. 28 Mesulam M-M., Geula C., Moran M.A. Ann. Neurol. 22:1987;683-691.
29. 29 Parasuraman R., Haxby J.V. Neuropsychologia. 7:1993;242-272.
30. 30 Greene J.D.W., Hodges J.R., Baddeley A.D. Neuropsychologia. 33:1995;1647-1670.
31. 31 Pashler H.E. The Psychology of Attention. 1998;MIT Press.
32. 32 Parasuraman R., Greenwood P.M. Parasuraman R. The Attentive Brain. 1998;461-487 MIT Press.
33. 33 Burns A., Jacoby R., Levy R. J. Am. Geriatr. Soc. 39:1991;39-45.
34. 34 Fadel, J., Sarter, M. and Bruno, J.P. Neuroscience (in press).
35. 35 Sarter M., Bruno J.P. Brain Res. Rev. 27:1998;143-156.
36. 36 Zaborszky L., Cullinan W.E., Braun A. Napier T.C., Kalivas P.W., Hanin I. The Basal Forebrain. 1991;43-100 Plenum Press.
37. 37 Aston-Jones, G. et al. (1996) in Progress in Brain Research (Vol. 107) (Holstege, G., Bandler, R. and Saper, C.D., eds), pp. 379-402, Elsevier.
38. 38 Fort P.et al. Eur. J. Neurosci. 7:1995;1502-1511.
39. 39 Sarter M., Bruno J.P. Trends Neurosci. 17:1994;539-550.
40. 40 Bourdelais A., Kalivas P.W. Brain Res. 577:1992;306-311.
41. 41 Swerdlow N.R., Braff D.L., Geyer M.A. Brain Res. 532:1990;146-150.
42. 42 Moore H.et al. Neuroscience. 88:1998;811-822.
43. 43 Weinberger D.R. Arch. Gen. Psychiatry. 44:1987;660-669.
44. 44 Breier A.et al. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2569-2574.
45. 45 Grace A.A.et al. Trends Neurosci. 20:1997;31-37.
46. 46 Lidow M.S., Williams G.V., Goldman-Rakic P.S. Trends Pharmacol. Sci. 19:1998;136-140.
47. 47 Mulder A.B.et al. Neuroscience. 72:1996;1009-1021.
48. 48 Wan F-J., Swerdlow N.R. Brain Res. 722:1996;168-176.
49. 49 Taber M.T., Fibiger H.C. J. Neurosci. 15:1995;3896-3904.
50. 50 Blaha C.D.et al. Eur. J. Neurosci. 9:1997;902-911.
51. 51 Lipska B.K.et al. Brain Res. 585:1992;1-6.
52. 52 Wilkinson L.S.et al. Behav. Brain Res. 55:1993;143-150.
53. 53 Gray J.A.et al. Behav. Brain Res. 71:1995;19-31.
54. 54 Gray J.A.et al. Behav. Brain Sci. 14:1991;1-84.
55. 55 Venables P.H. Maher B.A. Progress in Experimental Personality Research. 1964;1-47 Academic Press.
56. 56 Sarter M. Psychopharmacology. 114:1994;539-550.
57. 57 Mar C.M., Smith D.A., Sarter M. Br. J. Psychiatry. 169:1996;781-789.
58. 58 Nestor P.G., O'Donnell B.F. Parasuraman R. The Attentive Brain. 1998;527-546 MIT Press.
59. 59 Holley L.A.et al. Psychopharmacology. 120:1995;99-108.
60. 60 Haroutounian V.et al. Schizophren. Res. 12:1994;137-144.
61. 61 Gershon S., Shaw F.H. Lancet June. 24:1961;1371-1374.
62. 62 Tandon R., Greden J.F., Haskett R.F. Schizophr. Res. 9:1993;19-23.
63. 63 Wolkowitz O.M., Pickar D. Am. J. Psychiatry. 148:1991;714-726.
64. 64 Llorca P.M., Wolf M.A., Estorges J.P. Eur. Psychiatry. 6:1991;217-222.
65. 65 Jaspert A., Ebert D. Nervenarzt. 65:1994;62-65.
66. 66 Cash D.J., Serfözö P., Allan A.M. J. Pharmacol. Exp. Ther. 283:1997;704-711.
67. 67 Gray J.A. Neuropsychologia. 33:1995;1143-1153.
68. 68 Pontieri F.E., Tanda G., Di Chiara G. Proc. Natl. Acad. Sci. U. S. A. 92:1995;12304-12308.
69. 69 Wickelgren I. Science. 278:1997;35-37.
70. 70 Segal D.S., Geyer M.A., Schuckit M.A. Youdim B.H.et al. Essays in Neurochemistry and Neuropharmacology. 1981;95-130 John Wiley & Sons.
71. 71 Bartlett E.et al. Neuropsychopharmacology. 16:1997;77-82.
72. 72 LeDuc P.A., Mittleman G. Psychopharmacology. 121:1995;407-427.
73. 73 Lieberman J.A., Kinon B.J., Loebel A.D. Schizophr. Bull. 16:1990;97-110.
74. 74 Lieberman J.A., Sheitman B.B., Kinon B.J. Neuropsychopharmacology. 17:1997;205-229.
75. 75 Kalivas P.W., Stewart J. Brain Res. Rev. 16:1991;223-244.
76. 76 Robinson T.E., Berridge K.C. Brain Res. Rev. 18:1993;247-291.
77. 77 Kalivas P.W.et al. J. Psychopharmacol. 12:1997;49-53.
78. 78 Day J.C.et al. Eur. J. Neurosci. 9:1997;1130-1136.
79. 79 Di Chiara G. J. Psychopharmacol. 12:1997;54-67.
80. 80 Weinstein A.et al. J. Psychopharmacol. 12:1997;31-38.
81. 81 Grant S.et al. Proc. Natl. Acad. Sci. U. S. A. 93:1996;12040-12045.
82. 82 Deller T., Sarter M. Psychopharmacology. 137:1998;410-414.
83. 83 Crider A., Solomon P.R., McMahon M.A. Biol. Psychiatry. 17:1982;351-361.
84. 84 Tremblay N., Warren R.A., Dykes R.W. J. Neurophysiol. 64:1990;1212-1222.
85. 85 Eysenck M.W. Briley M., File S.E. New Concepts in Anxiety. 1991;418-433 CRC Press.
86. 86 Berntson G.G.et al. Behav. Brain Res. 74:1996;91-103.
87. 87 Neafsey, E.J. (1990) in Progress in Brain Research (Vol. 85) (Uylings, H.B.M. et al., eds), pp. 147-166, Elsevier.
88. 88 Zaborszky, L., Cullinan, W.E. and Luine, V.N. (1993) in Progress in Brain Research (Vol. 98) (Cuello, A.C., ed.), pp. 31-49, Elsevier.
89. 89 Berntson G.G., Sarter M., Cacioppo J.T. Behav. Brain Res. 94:1998;225-248.
90. 90 Brockington I. Eur. Psychiatry. 7:1992;203-207.
91. 91 Sarter M., Berntson G.G., Cacioppo J.T. Am. Psychol. 51:1996;13-21.
92. 92 Posner M.I. Proc. Natl. Acad. Sci. U. S. A. 91:1994;7398-7403.
93. 93 Mesulam M-M. Ann. Neurol. 28:1990;597-613.
94. 94 Heimer, L. et al. (1996) in Progress in Brain Research (Vol. 87) (Holstege, G., ed.), pp. 109-165, Elsevier.
95. 95 Andreasen N.C. Science. 275:1997;1586-1592.